Lymphoma Rounds: New England – POSTPONED

The Westin Copley Place (click here for directions)
10 Huntington Avenue
Boston, MA 02116

6:00 PM – 8:30 PM

The New England Lymphoma Rounds program has been postponed due to the evolving situation with the novel coronavirus (COVID-19).  For updates, please ensure you are subscribed to receive emails from the Lymphoma Research Foundation.


Robin Joyce, MD
Beth Israel Deaconess Medical Center

Ann LaCasce, MD, MSc
Dana-Farber Cancer Institute

Adam Olszewski, MD
Brown University School of Medicine

This program is free for healthcare professionals; however, pre-registration is required. Food and refreshments will be provided for all registered participants.

Please note: Only representatives from supporting pharmaceutical companies are invited to register. If your company is interested in becoming a Lymphoma Rounds supporter please contact Sarah Quinlan, LRF, at  Exhibit opportunities are also available, however, space is limited.

Companies that have secured a national exhibit sponsorship for Lymphoma Rounds must still rsvp by emailing Sarah Quinlan ( at least one week before the program to confirm their attendance. Otherwise, an exhibit table will not be guaranteed.

The Lymphoma Rounds program provides a forum for local practicing physicians from academic and community medical centers to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Physicians network, share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the local area.

At the conclusion of this educational activity, the participant should be better able to:

  • Summarize the latest developments in lymphoma diagnosis, treatment and management.
  • Apply best practices for treating lymphoma patients.
  • Inform patients about potential clinical trial opportunities.
  • Establish a network of health care professionals who work with lymphoma patients.

This program will complete the 2019-20 New England Rounds series.

New England Lymphoma Rounds Steering Committee

Baystate Medical Center
Armen Asik, MD
Beth Israel Deaconess Medical Center
Jon Arnason, MD
Robin Joyce, MD
Boston University School of Medicine
J. Mark Sloan, MD
Brown University School of Medicine/Rhode Island
Adam Olszewski, MD
Dana-Farber Cancer Institute
Jorge Castillo, MD
Ann LaCasce, MD, MSc
Dartmouth–Hitchcock Medical Center
Elizabeth Bengtson, MD
Erick Lansigan, MD
Lahey Hospital and Medical Center
Tarun Kewalramani, MD
Massachusetts General Hospital Cancer Center
Jeremy Abramson, MD, MSc (chair)
Jeffrey Barnes, MD, PhD
Saint Francis Hospital
Syed Ali, MD
Tufts University Cancer Center
Andreas Klein, MD
UMass Memorial Medical Center
Jan Cerny, MD, PhD, FACP
Muthalagu Ramanathan, MD
University of Vermont College of Medicine
Julian Sprague, MD, PhD
Yale University School of Medicine
Francine Foss, MD

Joint Providership Statement

This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and the Lymphoma Research Foundation.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Statement

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Lymphoma Research Foundation and the University of Nebraska Medical Center, Center for Continuing Education

This activity is supported by educational grants from:
AbbVie, Inc., Acrotech Biopharma, LLC, AstraZeneca, BTG International, Inc., Celgene Corporation, Janssen Scientific Affairs, LLC and Pharmacyclics, LLC, an AbbVie Company, Kite Pharma, Inc., Novartis Pharmaceuticals Corporation, Seattle Genetics, Inc., TG Therapeutics, Inc. and Verastem, Inc.